

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement accompanies the new patent application submitted herewith of the following Inventors: John T. Gwynne, Philippe John Robert Vitou, Bruce Paul Randazzo;

For: Combination Therapy for Type II Diabetes or Syndrome X.

1. **Preliminary Statements**

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

2. ☒ **Previously Cited Information**

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Application Number 10/163,707 filed on June 6, 2002 of John T. Gwynne, et al for Combination Therapy for Type II Diabetes or Syndrome X.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV 238504649 US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

3/1/04
Date

Kerry A. D'Ovidio
Kerry A/D'Ovidio

3. ☐ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed, except that no copy of a pending U.S. application, a U.S. patent, or a U.S. patent application publication is enclosed.
4. ☐ Concise Explanation
Documents cited above which are not in the English Language
a. ☐ have been explained in the specification.
b. ☐ have an abstract (or other concise explanation) in English enclosed or, if readily available, a translation into English of the document is enclosed.
5. Form PTO-1449 is enclosed in duplicate.
6. Customer Number 25291.



Christine P. Bellon
Attorney for Applicants
Reg. No. 41,611

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (617) 665-8653

S:\LACOMMON\PATENTS\AM #'s folder\AM100761\DIV\IDS 2-27-04..doc

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	Not Yet Assigned	
			Filing Date		
			First Named Inventor	John T. GWYNNE	
			Group Art Unit		
Examiner Name					
Sheet	1	of	1	Attorney Docket Number	AM100761-D1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	2.	WO	99/18932		Dileep Bhagwat et al.	04-22-1999		<input type="checkbox"/>
	3.	WO	99/29314		Peter Timmins et al.	06-17-1999		<input type="checkbox"/>
	4.	WO	99/61435	A1	Jay Wrobel et al.	12-02-1999		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T
	5.	REAVEN et al., The American Journal of Medicine, 60, 80-88 (1976)			<input type="checkbox"/>
	6.	STOUT, Metabolism, 34(12), 7-12 (1985)			<input type="checkbox"/>
	7.	PYÖRÄLÄ et al., Diabetes/Metabolism Reviews, 3(2), 463-524 (1987)			<input type="checkbox"/>
	8.	R.J. JARRETT, Diabetes/Metabolism Reviews, 5(7), 547-558 (1989)			<input type="checkbox"/>
	9.	R. DEFONZO et al., Diabetes Care, 14(3), 173-194 (1991)			<input type="checkbox"/>
	10.	H.U. HARING, Diabetologia, 34,848-861 (1991)			<input type="checkbox"/>
	11.	B.J. GOLDSTEIN, J. Cellular Biochemistry, 48, 33-42 (1992)			<input type="checkbox"/>
	12.	B.J. GOLDSTEIN, Receptor, 3, 1-15 (1993).			<input type="checkbox"/>
	13.	F. AHMAD et al., Biochimica et Biophysica Acta, 1248, 57-69 (1995)			<input type="checkbox"/>
	14.	MCGUIRE et al., Diabetes, 40, 939-942 (1991)			<input type="checkbox"/>
	15.	MEYEROVITCH et al., J. Clinical Invest., 84, 976-983 (1989)			<input type="checkbox"/>
	16.	SREDY et al., Metabolism, 44, 1074-1081 (1995)			<input type="checkbox"/>
	17.	HARRIS et al., Diabetes in America, Chapter 29, 1-48 (1985)			<input type="checkbox"/>

S:\LACOMMONPATENTS\AM #'s folder\AM100761\DIV\PTO 1449 2-27-04.doc

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.